Johnson agrees to bid dollars 900m for Neutrogena
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.JOHNSON & Johnson, famed for its baby-care products, has agreed to acquire Neutrogena, the toiletries maker, for more than dollars 900m, in another move towards consolidation in the health care business.
An all-cash tender for the company's 25.7 million shares, including almost 10 million held by its chief executive, Lloyd Cotsen, will begin on Friday. Analysts said a higher bid could emerge, although the company would have to pay Johnson & Johnson a 'break-up fee' of dollars 27.5m.
The price, dollars 35.25 a share, is a considerable premium to Neutrogena's share price and a high multiple of its sales, about dollars 300m last year. The acquisition will dilute Johnson & Johnson's earnings by perhaps five cents a share unless cost-cutting follows the takeover.
Johnson & Johnson shares fell 25 cents to dollars 48 3/4 , while Neutrogena gained dollars 6 1/8 to dollars 24 7/8 .
Neutrogena - whose shares traded at dollars 20 1/8 as recently as 5 August - has been a rumoured takeover target for several weeks, with Johnson & Johnson and Procter & Gamble mentioned as likely buyers.
The run-up in the share price in anticipation of a deal will almost certainly add to recent complaints about an apparent resurgence of insider trading on Wall Street.
The purchase of the Los Angeles-based manufacturer of premium hair and skin care products comes at a time big pharmaceutical and health care companies are finding it increasingly difficult to raise prices, particularly on the drugs side.
At the same time, their balance sheets are in good shape to make big acquisitions.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments